On March 11, 2021 PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, reported an e-poster presentation featuring nonclinical data of PMC-309 at American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, PharmAbcine, MAR 11, 2021, View Source [SID1234576554]). The meeting will take place virtually over April 10-15 and May 17-21 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title: PMC309, a highly selective anti-VISTA antibody enhances T cell activation through blocking the interaction of T cells and myeloid derived suppressor cells (MDSC)
Session category/title: Immunology/Immune Checkpoints
Abstract number: 1116
Poster number: 1626
Presentation Type: E-poster with audio presentation
Date: April 10, 2021
PMC-309 is a novel monoclonal IgG (Immunoglobulin G) targeting human VISTA (V-domain Ig Suppressor of T cell Activation) expressed primarily on MDSC (Myeloid-Derived Suppressor Cells). PMC-309 is one of the company’s first in class immuno-oncology drug candidates. It can provide a promising immunotherapeutic strategy through the inhibition of VISTA-positive immunosuppressive cell activities.
"We are delighted to share the data that validate PMC-309’s unique mode of action and its therapeutic effect in the preclinical setting," said Dr. Jin-San Yoo, CEO of PharmAbcine. "We find the data highly encouraging, and this will give us added confidence in preparing PMC-309 for global Phase I trial in 2022."